Gold prices slip slightly after recent gains; U.S. data eyed
SEATTLE - Perspective Therapeutics, Inc. (NYSE AMERICAN:CATX), currently trading at $4.19 and showing strong momentum with a 36% year-to-date return according to InvestingPro, announced Thursday that updated data from its [212Pb]VMT-α-NET program for treating neuroendocrine tumors will be presented at the European Society of Medical Oncology Congress in October 2025.
The presentation will feature mature safety and preliminary efficacy data from 44 patients in the first two dose-finding cohorts of the company’s clinical trial. Dr. Thorvardur Halfdanarson from Mayo Clinic Comprehensive Cancer Center will deliver the mini oral presentation on October 20 in Berlin, Germany.
Perspective’s [212Pb]VMT-α-NET therapy is designed to target and deliver the alpha-emitting isotope 212Pb to tumor sites expressing somatostatin receptor 2 (SSTR2). The company is currently conducting a multi-center, open-label study in patients with unresectable or metastatic SSTR2-positive neuroendocrine tumors who have not previously received radiopharmaceutical therapy.
The company reopened Cohort 2 of the study in August 2024 and enrolled an additional 33 patients through April 30, 2025. Some of these patients will have had at least 32 weeks of follow-up after their initial doses by the second half of 2025, providing sufficient time for evaluation after treatment. While analysts have revised earnings estimates upward, InvestingPro data indicates the company is experiencing accelerated cash burn, with operating cash flow remaining negative in the last twelve months.
Perspective Therapeutics is developing radiopharmaceutical treatments that use alpha-emitting isotopes to deliver radiation specifically to cancer cells through specialized targeting molecules. The company is also developing complementary imaging diagnostics using the same targeting approach.
The announcement was made in a press release issued by the company.
In other recent news, Perspective Therapeutics Inc. has been the subject of various analyst updates following its recent presentations and business activities. RBC Capital analysts raised the company’s stock price target to $16, citing promising data from Perspective’s NET program presented at the American Society of Clinical Oncology (ASCO). The program demonstrated a competitive objective response rate and maintained best-in-class safety, according to the analysts. Meanwhile, Oppenheimer analysts adjusted their price target for the company to $15, while still maintaining an Outperform rating. This revision followed the company’s first-quarter results and a business update, highlighting active enrollment in clinical programs for neuroendocrine tumors, melanoma, and other conditions.
Additionally, Perspective Therapeutics announced the results of its 2025 Annual Meeting of Stockholders, where a quorum was achieved with 82.17% of shares represented. Key decisions included the election of five board members, with Lori A. Woods receiving the highest number of "for" votes. The company also shared its ongoing research efforts at ASCO, although no new details were provided about discussions with the FDA regarding their VMT-α-NET program. These developments reflect the company’s ongoing efforts in advancing its clinical programs and engaging with stakeholders.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.